Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nasalcrom

This article was originally published in The Tan Sheet

Executive Summary

FDA requests studies in the pediatric population for Pharmacia & Upjohn's cromolyn sodium nasal spray. If P&U submits studies that are considered sufficient by the agency, Waxman/Hatch marketing exclusivity for the product would be extended by six months from its current expiration on Jan. 3, 2000. The product, which is indicated for both prevention and treatment of allergy symptoms, was approved in January 1997 ("The Tan Sheet" Jan. 13, 1997, p. 1). The original sponsor of the drug was McNeil Consumer Healthcare; P&U acquired the brand in a June 1997 trade with McNeil ("The Tan Sheet" June 9, 1997, p. 2)
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS089298

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel